All In Biotech

Drug Trial Radar · NCT07728097

A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS

A Phase 3b/4, Interventional, Prospective, Multicenter, Open-Label Study Evaluating the Effectiveness of a Gradual Titration Regimen to Optimize CBD-OS as Add-On Therapy in Adults With Lennox-Gastaut Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 18, 2026

Primary completion

Dec 28, 2028

Study completion Dec 28, 2028

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
Collaborators
Jazz Pharmaceuticals Research UK Limited
First posted
Jul 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3b/Phase 4 study. The purpose of this study is to learn more about the efficacy of using CBD-OS as an add-on therapy for the treatment of LGS in adults.

Conditions

  • Lennox-Gastaut Syndrome

Interventions

  • Cannabidiol Oral SolutionDrug

    100 mg/ml Cannabidiol Oral solution (CBD-OS)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting 50% or more reduction in their 28-day average countable major motor seizure frequencyTime frame: End of Treatment Period, Week 24

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Neuro Pain Research Center

    Fresno, California

  • Louisiana State University Health Sciences Center New Orleans

    New Orleans, Louisiana

  • Velocity Clinical Research At Raleigh Neurology

    Raleigh, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.